Abexinostat

Drug Profile

Abexinostat

Alternative Names: CG-781; CRA-024781; PCI-24781; S 78454

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Celera Genomics Group
  • Developer GlaxoSmithKline; Massachusetts General Hospital; Pharmacyclics; Servier; University of California at San Francisco
  • Class Amides; Antineoplastics; Benzofurans; Dimethylamines; Hydroxamic acids; Phenyl ethers; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma
  • Phase I/II Sarcoma
  • Phase I Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Breast cancer; Myelodysplastic syndromes; Nasopharyngeal cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 24 Feb 2017 Xyomic Pharmaceuticals acquires abexinostat from Pharmacyclics
  • 24 Feb 2017 Xyomic Pharmaceuticals plans pivotal phase III trials in solid tumours worldwide
  • 10 May 2016 Efficacy and adverse events data from a phase-I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top